MedTrace Logo

Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

NCT05863273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2025-03-17

No results posted yet for this study

Summary

This is a multicenter, one-arm, prospective, observational study，intended to assess evaluation of efficacy and safety of Apremilast in Chinese patients with moderate-to-severe plaque psoriasis。During this study, it is expected to collect data at at baseline and weeks 2, 6, 10, 16, and 20 after treatment。

Conditions

Interventions

DRUG

Apremilast

Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    lead OTHER

Principal Investigators

  • Xinghua Gao, MD · First Hospital of China Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2025-02-10
Completion
2025-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05863273 on ClinicalTrials.gov